MORRISVILLE – Metabolon is gearing up to further drive its global mission in precision medicine and drug research through study of the metabolome with $25 million in new equity funding.
The metabolome refers to the complete set of small-molecule chemicals found within a biological sample.
Metabolon recently signed a testing agreement with Mayo Clinic.
Metabolon studies more than genetics as part of its research efforts, deciphering “thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways,” the company says.
Biotech deep dive: Inside Metabolon’s biomarker testing agreement with Mayo Clinic
“The proceeds will be used for general corporate purposes, helping Metabolon further accelerate commercialization activities and continue advancing its well-defined R&D roadmap,” the privately held company said in the funding announcement.
“Metabolon is experiencing significant growth, and we are excited to continue building our talented team and scaling our capabilities to meet increasing demand,” said Rohan Hastie, Metabolon’s CEO. “Metabolomics is an essential component of the life science ecosystem. All omics approaches – genomics, proteomics, metabolomics – are highly complementary. You cannot fully understand biology, and more specifically systems biology, by just looking at DNA, proteins, or metabolites exclusively. As life sciences evolve toward a more sophisticated multi-omics approach, Metabolon is fast becoming an industry standard and a critical step toward true precision medicine.”
In November 2021 Metabolon unveiled a new platform for study of the metabolome.
‘Demystifies’ the gut: RTP biotech Metabolon unveils new metabolome platform
And the company enjoyed a successful 2022, according to Chief Financial Officer Gerry Haines.
“This financing arrives on the heels of record revenue and margins in 2022 and comes predominantly from new investors, with additional participation by existing investors,” Haines said in the funding announcement. “The infusion of capital will allow us to continue accelerating our already robust growth and execution as we bring market-leading metabolomics and the associated deep phenotyping capabilities to a rapidly expanding market”
